nab-Paclitaxel + Cisplatin + Gemcitabine
Phase 2Small molecule
nab-Paclitaxel + Cisplatin + Gemcitabine is one of 55 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
164 competitors in Pancreatic Adenocarcinoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Eloxatin
TevaPhase 3
Plavix
SanofiPhase 3
Mfolfirinox
IncytePhase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Camptosar
PfizerPhase 2
Imfinzi
AstraZenecaPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Imjudo
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHonorHealth Research Institute